Rafael Holdings, Inc. 8-K

What Happened

• On June 10, 2026, Rafael Holdings, Inc. (RFL) filed a Form 8-K and posted a press release announcing that the last patient completed the final 96-week study visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for Niemann‑Pick Disease Type C.
• The company said topline data from the main study cohort is expected to be announced in the second half of 2026. The filing notes the information is furnished under Regulation FD and contains forward‑looking statements and is not “filed” for SEC incorporation purposes.

Key Details

• Press release and 8-K filed on June 10, 2026 (Exhibit 99.1).
• Final 96‑week visit completed by the last patient in the pivotal Phase 3 TransportNPC study.
• Topline data from the main cohort expected in H2 2026.
• The 8-K did not disclose earnings, revenue, or other financial figures; it included standard forward‑looking statement cautions.

Why It Matters

• Completion of the final 96‑week visit signals the end of the planned patient follow‑up period for the pivotal trial, and investors should watch the announced H2 2026 topline results for new clinical data.
• The filing did not provide financial results or operational metrics; separate SEC disclosures would be needed for any earnings, revenue or material financial updates.
• The press release is furnished under Regulation FD and contains forward‑looking statements, so investors should review the full release and subsequent filings for further details.